Henok Asfaw

Henok Asfaw

Auto-generated profile, based on publicly available information

Henok Asfaw

Institut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HAHenok Asfaw
Henok Asfaw
KLKatja Laqua
Katja Laqua
AWAnna Maria Walkowska
Anna Maria Walkowska
FCFraser Cunningham
Fraser Cunningham
MMMaria Santos Martinez-Martinez
Maria Santos Martinez-Martinez
PIPeter Imming
Peter Imming
Wollamide B is a cationic antimycobacterial cyclohexapeptide that exhibits activity against Mycobacterium bovis (M. bovis) (IC50 of 3.1 μM). Aiming to define its structural activity relationship (SAR), optimizing potency and pharmacokinetic properties, libraries of analogues were synthesized following a standard Fmoc-based solid phase peptide synthesis approach. The antimycobacterial activities of wollamide B and all the synthesized analogues were tested against Mycobacterium tuberculosis (Mtb) H37Rv. Parallely, in vitro drug metabolism and pharmacokinetic (ADME) profiling was done for the synthesized compounds to evaluate their drug likeness. Among the 25 synthesized wollamides five of them showed potent activities with MICs ≤ 3.1 μM and found to be nontoxic against human HepG2 cells up to 100 μM. The results of the in vitro ADME profiling revealed the remarkable plasma stability and very good aqueous solubility of the class in general while the metabolic stability was found to be moderate to low. Of particular note, compounds 7c (MIC = 1.1 μM) and 13c (0.6 μM) that exhibited good balance of antimycobacterial activity vs. optimal pharmacokinetic properties could be used as a new lead for further development.